Peptides
Clinician and regulatory review
Peptide pathways are assessed individually. Evidence, indication, product status, patient suitability and South African regulatory requirements determine whether a pathway can be considered.
Treatment pathways
Peptide & IV Therapies
The clinic brings together clinician-governed peptide and amino-acid pathways with IV services, while distinguishing established treatments from investigational or restricted products.
IV therapy
Targeted rather than generic
IV services are selected according to the specific ingredients, clinical objective and patient history. Intravenous delivery is treated as a medical procedure rather than automatically being superior to oral treatment.
Eligibility
Assessment before access
Where a treatment requires clinical authorisation, new patients are directed to the assessment pathway. Existing assessed patients can be managed according to their recorded eligibility and care plan.
Catalogue
View the current offering
The treatment catalogue provides individual pages with background, evidence context, availability and the appropriate route to assessment or purchase.